Skip to content
| Eingeschlossene Patienten: 20.277 (Stand 1. März 2021) | |
| Amgevita® (Adalimumab) | 110 |
| Benepali® (Etanercept) | 767 |
| Cimzia® (Certolizumab) | 946 |
| Enbrel® (Etanercept) | 2865 |
| Erelzi® (Etanercept) | 335 |
| Flixabi® (Infliximab) | 9 |
| Hulio® (Adalimumab) | 65 |
| Humira® (Adalimumab) | 2903 |
| Hyrimoz® (Adalimumab) | 85 |
| Idacio® (Adalimumab) | 23 |
| Imraldi® (Adalimumab) | 107 |
| Inflectra™ (Infliximab) | 16 |
| Jyseleca® (Filgotinib) | 6 |
| Kevzara® (Sarilumab) | 154 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1458 |
| Nepexto® (Etanercept) | 8 |
| Olumiant® (Baricitinib) | 432 |
| Orencia® (Abatacept) | 862 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 11 |
| Rinvoq® (Upadacitinib) | 124 |
| Rixathon® (Rituximab) | 17 |
| RoActemra® (Tocilizumab) | 1331 |
| Simponi® (Golimumab) | 447 |
| Xeljanz® (Tofacitinib) | 337 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 6006 |
